Source: Eur Respir J 2016; 47: 35-38



Rating:

Share or cite this content

Citations should be made in the following way:
Balbi Bruno, Ferrarotti Ilaria, Miravitlles Marc. Efficacy of augmentation therapy for emphysema associated with alpha1-antitrypsin deficiency: enough is enough. Eur Respir J 2016; 47: 35-38

Member's Comments

No comment yet.

Related content which might interest you: Current and future therapy of lung emphysema caused by alpha-1-antitrypsin deficiency Source: Annual Congress 2004 - Alpha-1-antitrypsin deficiency: Current knowledge and new frontiers Year: 2004 Effect of augmentation therapy on immune function of patients with severe Alpha1-antitrypsin deficiency Source: Annual Congress 2012 - COPD treatments: efficacy and safety Year: 2012 Effect of intravenous alpha-1-antitrypsin augmentation therapy on proteinase-3-generated AaVal541 in deficient patients Source: Virtual Congress 2021 – Airway pharmacology: translational and basic science Year: 2021 Pulmonary administration of alpha1-antitrypsin for the treatment of Alpha1-antitrypsin deficiency Source: Eur Respir J 2003; 22: Suppl. 45, 385s Year: 2003 SPARTA: Efficacy and safety assessment of two regimens of alpha1-proteinase inhibitor in emphysema due to alpha1-antitrypsin deficiency Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013 Long-term effect of alpha-1-antitrypsin augmentation therapy on the decline of FEV1 in deficient patients Source: Virtual Congress 2021 – Treatments for airway diseases Year: 2021 Comparison of outcomes in augmentation naïve and augmented patients with alpha-1 antitrypsin deficiency related lung disease. Source: International Congress 2019 – COPD clinical studies: bronchodilators, corticosteroids and more Year: 2019 Use of measurements of airway resistance in the determination of reversibility in patients with emphysema associated with alpha-1-antitrypsin (A1ATD) deficiency Source: Eur Respir J 2001; 18: Suppl. 33, 205s Year: 2001 The effect of augmentation therapy on systemic and pulmonary inflammation markers in α1-antitrypsin deficiency patients Source: Annual Congress 2010 - Recent developments of molecular pathology and functional genomics in non-neoplastic and neoplastic lung diseases Year: 2010 Aα360: A measure of disease and treatment efficacy in alpha-1-antitrypsin (A1AT) deficiency Source: Annual Congress 2010 - COPD: phenotyping and monitoring Year: 2010 Endobronchial valve treatment in patients with severe emphysema due to alpha-1 antitrypsin deficiency. Source: International Congress 2019 – Interventional pulmonology: diagnostic techniques and obstructive airway disease Year: 2019 Short-term variability of biomakers of proteinase activity in patients with emphysema associated with type Z alpha-1-antitrypsin deficiency Source: Eur Respir J 2004; 24: Suppl. 48, 459s Year: 2004 Impact of alpha 1-antitrypsin deficiency and prior augmentation therapy on patients' survival after lung transplantation Source: Eur Respir J, 50 (3) 1700962; 10.1183/13993003.00962-2017 Year: 2017 Role of bronchiectasis in alpha1-antitrypsin deficiency patients: a comparative analysis Source: International Congress 2019 – Chronic cough, a1-antitrypsin deficiency and other conditions Year: 2019 Prevalence of alpha1-antitrypsin deficiency and its influence on lung function decline in patients with severe asthma Source: Virtual Congress 2020 – Advances in asthma treatment Year: 2020 Effect of 2-Year therapy with Roflumilast in severe systemic inflammation in COPD with metabolic syndrome Source: International Congress 2019 – Advances in COPD pharmacology Year: 2019 Long-term safety of combination therapy with nintedanib and pirfenidone in Japanese patients with IPF Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Lung deposition of inhaled alpha1-proteinase inhibitor in cystic fibrosis and alpha1-antitrypsin deficiency Source: Eur Respir J 2009; 33: 354-360 Year: 2009 Efficacy and safety of inhaled a1-antitrypsin in patients with severe a1-antitrypsin deficiency and frequent exacerbations of COPD Source: Eur Respir J, 54 (5) 1900673; 10.1183/13993003.00673-2019 Year: 2019 Severe fibrotic lung disease – How much therapy is too much therapy? Source: Annual Congress 2008 - Clinical Grand Round - an interactive session Year: 2008